Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gilenya for Abrogation of IF/TA in Kidney Transplantation
NCT05285878Phase 2Enrolling by invitation
- Sponsor
- Houston Methodist Research Institute
- Start
- Jul 2022
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 2 trial of fingolimod in Interstitial Fibrosis And Tubular Atrophy (IF/TA), sponsored by Houston Methodist Research Institute. Started Jul 2022; status: enrolling by invitation.
02
Drugs
fingolimod
03
Conditions
Interstitial Fibrosis And Tubular Atrophy (IF/TA)
Beyond the preview
Go deeper on NCT05285878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05285878.